Last reviewed · How we verify
amisulpride and risperidone
At a glance
| Generic name | amisulpride and risperidone |
|---|---|
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Magnetic Seizure Therapy for Psychotic Disorders (NA)
- Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT) (PHASE3)
- Definitive Selection of Neuroimaging Biomarkers for the Diagnosis and Treatment to Common Mental Disorders (NA)
- Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis (PHASE2)
- Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients
- Prolactin Change in Chinese Patients With Schizophrenia After Antipsychotics Treatment
- Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients
- Antipsychotic Induced Structural and Functional Brain Changes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- amisulpride and risperidone CI brief — competitive landscape report
- amisulpride and risperidone updates RSS · CI watch RSS
- Sanofi portfolio CI